MET
MET exon 14 skipping mutations and MET amplification in NSCLC. Targeted by capmatinib, tepotinib, savolitinib.
No Clinical Trials found for this biomarker.
MET exon 14 skipping mutations and MET amplification in NSCLC. Targeted by capmatinib, tepotinib, savolitinib.
No Clinical Trials found for this biomarker.